X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CADILA HEALTHCARE - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CADILA HEALTHCARE AUROBINDO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 14.7 23.9 61.5% View Chart
P/BV x 3.8 6.0 63.3% View Chart
Dividend Yield % 0.4 0.8 52.4%  

Financials

 AUROBINDO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
AUROBINDO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs895460 194.6%   
Low Rs622305 203.9%   
Sales per share (Unadj.) Rs254.692.1 276.4%  
Earnings per share (Unadj.) Rs39.314.8 265.1%  
Cash flow per share (Unadj.) Rs46.618.5 252.0%  
Dividends per share (Unadj.) Rs2.503.20 78.1%  
Dividend yield (eoy) %0.30.8 39.4%  
Book value per share (Unadj.) Rs160.068.0 235.3%  
Shares outstanding (eoy) m585.881,023.74 57.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.2 71.7%   
Avg P/E ratio x19.325.8 74.8%  
P/CF ratio (eoy) x16.320.7 78.7%  
Price / Book Value ratio x4.75.6 84.3%  
Dividend payout %6.421.6 29.5%   
Avg Mkt Cap Rs m444,390391,581 113.5%   
No. of employees `00014.016.9 83.0%   
Total wages/salary Rs m17,67815,002 117.8%   
Avg. sales/employee Rs Th10,667.85,594.5 190.7%   
Avg. wages/employee Rs Th1,264.3890.1 142.0%   
Avg. net profit/employee Rs Th1,645.8899.9 182.9%   
INCOME DATA
Net Sales Rs m149,15794,295 158.2%  
Other income Rs m1,1591,286 90.1%   
Total revenues Rs m150,31695,581 157.3%   
Gross profit Rs m34,34319,036 180.4%  
Depreciation Rs m4,2763,750 114.0%   
Interest Rs m667450 148.3%   
Profit before tax Rs m30,55816,122 189.5%   
Minority Interest Rs m50338 14.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m7,5971,289 589.3%   
Profit after tax Rs m23,01215,168 151.7%  
Gross profit margin %23.020.2 114.1%  
Effective tax rate %24.98.0 310.9%   
Net profit margin %15.416.1 95.9%  
BALANCE SHEET DATA
Current assets Rs m92,06260,223 152.9%   
Current liabilities Rs m66,22353,058 124.8%   
Net working cap to sales %17.37.6 228.0%  
Current ratio x1.41.1 122.5%  
Inventory Days Days10670 151.8%  
Debtors Days Days6888 76.8%  
Net fixed assets Rs m62,91972,984 86.2%   
Share capital Rs m5861,024 57.2%   
"Free" reserves Rs m93,13368,576 135.8%   
Net worth Rs m93,71969,600 134.7%   
Long term debt Rs m1,81424,684 7.3%   
Total assets Rs m162,494152,207 106.8%  
Interest coverage x46.836.8 127.1%   
Debt to equity ratio x00.4 5.5%  
Sales to assets ratio x0.90.6 148.2%   
Return on assets %14.610.3 142.0%  
Return on equity %24.621.8 112.7%  
Return on capital %32.717.9 182.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83821,280 356.4%   
Fx outflow Rs m30,22410,874 278.0%   
Net fx Rs m45,61310,406 438.3%   
CASH FLOW
From Operations Rs m32,78613,495 242.9%  
From Investments Rs m-17,870-29,103 61.4%  
From Financial Activity Rs m-19,15323,158 -82.7%  
Net Cashflow Rs m-4,2397,556 -56.1%  

Share Holding

Indian Promoters % 54.1 74.8 72.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 8.3 95.8%  
FIIs % 27.7 5.9 469.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 11.0 92.7%  
Shareholders   69,601 44,069 157.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Drops 230 Points as Trade War Fears Resurface(12:30 pm)

After opening the day flat, share markets in India witnessed choppy trading activity throughout the day and are presently below the dotted line.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 19, 2018 02:01 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS